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Abstract
Dilated cardiomyopathy (DCM) is a multifactorial heart disease in which there is enlargement
and systolic dysfunction of one or both ventricles. The exhaustion of compensatory mechanisms
leads to symptoms of congestive heart failure, which is a significant problem in contemporary
cardiology. DCM is still diagnosed using clinical assessment; echocardiography is necessary,
and in some clinical situations we need hemodynamic assessment in order to identify the
etiology and progression of heart disease. These tests are necessary for choice of treatment and
qualification for heart transplant. Investigators are looking for new, valuable, additional
parameters which could be of use in screening and heart disease progression assessment, and
which may be helpful in the management and risk stratification of patients with DCM. These
monitoring and prognostic tools in patients with chronic heart failure can be biomarkers, such
as natriuretic peptides: BNP and NT-proBNP, cardiac troponins or inflammatory cytokines
and their receptors. Moreover, there are ongoing research projects concerning persistently
elevated uric acid, Ca-125 and osteopontin concentrations for the identification of patients
with DCM, as well as adverse prognoses. (Cardiol J 2008; 15: 388–395)
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Dilated cardiomyopathy
Dilated cardiomyopathy (DCM) is a heart mu-
scle disease in which one or both heart ventricles
become enlarged and their pumping function is de-
creased.
The most frequent causes of dilating heart ven-
tricles include coronary thrombosis, particularly
after a heart attack, a dilated form of hypertensive
cardiomyopathy, infectious factors, inflammatory
immunology diseases, storage diseases, and, final-
ly, a hereditary or idiomatic form of DCM. Dilated
heart ventricles may also be a consequence of acqu-
ired cardiac valve defects, especially when they
have not been corrected by surgery or when the
surgery has not improved the function of the heart
muscle as expected [1]. Table 1 shows the collated
etiopathogenesis of dilated cardiomyopathy [2].
Table 1. Etiopathogenesis of dilated cardiomyo-
pathy [2].
Genetic — family cardiomyopathy
Idiopathic
Specific — ischemic:
— hypertensive
— inflammatory
— autoimmunology
— puerperal
— alcoholic
— metabolic (diabetic, in beriberi disease,
in obesity, in malabsorption syndrome)
— tachyarrhythmic
— catecholamine (in pheochromocytoma
and hyperthyroidism)
— postradiation
— iatrogenic (drug-induced)
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Hereditary DCM constitutes 30–50% of DCM
cases; it often co-exists with bradycardia, the slo-
wing of atrial-ventricular and intraventricular trans-
mission, dystrophy of skeletal muscles, myopathy,
deafness and mental disability. Most frequently, it
is inherited as an autosomal dominant. This form
of the disease includes the following mutations of
protein-coding genes [3]:
— cytoskeleton: desmin, tapasin, beta-sarcogly-
can, 8-sarcoglycan, dystrophin, metavinculin;
— intercellular connections: vinculin;
— nucleus: laminin, emerin;
— sarcomer: troponin T, heavy chain in beta-
-myosin, actin, telotonin;
— ionic channels: phospholamban (calcium
pump), a subunit of the heart potassium chan-
nel sensitive to triphosphate;
— mitochondrion DNA.
The exhaustion of compensation mechanisms
results in the occurrence of congestive heart failure
symptoms, which is a significant problem in modern
cardiology. According to the estimates of the Euro-
pean Society of Cardiology, this pathology may occur
in 0.4–2% of the European population [4]. The annual
death rate in the group of people suffering from heart
failure, independent of etiology, amounts to an avera-
ge of 10%, but depending on hemodynamic condition
it amounts to 12% of patients in the 2nd class accor-
ding to NYHA and even 56% of those in the 4th class
according to NYHA [5, 6].
Early diagnosis of DCM is of great prognostic
importance because an effective treatment started
at the beginning of the disease may stop its progress
and delay the development of symptomatic heart
failure. The basis of diagnosing DCM, especially in
Table 2. Anatomical changes occurring in dilated
cardiomyopathy
Dilation of the left ventricle
Changes in the shape of the left ventricle
(from ellipsoidal to spherical)
Changes in spatial configuration of the mitral valve
subvalvular apparatus
Enlargement of the left atrium, the right ventricle
and the right atrium
its latent phase, is a thorough clinical assessment.
Echocardiography is essential and, in some clinical
cases, a hemodynamic assessment may also be es-
sential to determine the etiology as well as to eva-
luate how advanced the heart failure is, and this
information is then used in the therapy and for qu-
alifying patients to heart transplant [7]. Valuable
additional biochemical parameters are currently
being searched for, which, together with clinical and
echocardiographic assessment, will bring new use-
ful information at various phases of the disease.
The role of echocardiography in
dilated cardiomyopathy
Echocardiography of a patient with DCM inclu-
des anatomical and functional assessment with the use
of all available techniques. In most cases, the left ven-
tricle is spherical in shape and global hypokinesis of
its walls can be observed (Fig. 1) Anatomical chan-
ges occurring in DCM are presented in Table 2.
Global function of the left ventricle depends on
the joint assessment of left ventricular filling volu-
me (diastolic function) as well as on left ventricular
ejection fraction (systolic function).
Echocardiographic and Doppler indicators of an
unfavourable prognosis in DCM are presented in
Table 3 [8].
Natriuretic peptides:
BNP and NT-proBNP in diagnosing
dilated cardiomyopathy
Early diagnosis of DCM in its initial phase ena-
bles the start of effective treatment with the pur-
pose of stopping the progress of the disease and
delaying the development of symptomatic heart fa-
ilure. Regarding this fact, scientists are searching
for routine and widely accessible diagnostic me-
thods which could be used in assessing the state of
advancement of the disease and in controlling the
results of treatment and the prognosis. Such a role
Figure 1. Apical four-chamber projection in patient
showing dilated cardiomyopathy and incorrect shape
of the left ventricle.
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may be played by natriuretic peptides, especially
brain natriuretic peptide (BNP) and N-terminal pro-
hormone brain natriuretic peptide (NT-proBNP).
Concentrations of BNP and NT-proBNP in blood se-
rum are similar in healthy people, but in people with
heart failure the concentration of NT-proBNP is
2–10 times higher than that of BNP. BNP is secre-
ted into blood as a biologically active and shorter
peptide, and NT-proBNP is secreted as a biologi-
cally inactive NH2 — the final part. They are se-
creted in equal amounts but BNP has a shorter half-
life in blood serum and, as a consequence, its con-
centration is lower. A factor stimulating the
secretion of BNP is the stretching of myocytes ra-
ther than the pressure load itself [9, 10]. BNP cau-
ses a dose dependent decrease of arterial pressure
resulting in direct vasodilatation and movement of
intravascular volume into extravascular space
(which is a result of vascular endothelium increased
permeability and of increased hydrostatic pressure
in the capillary bed). Other mechanisms decreasing
initial load are diuresis and natriuresis, which also
inhibit the activity of the renin–angiotensin–aldo-
sterone system. Natriuretic peptides inhibit adre-
nergic stimulation through central suppression of
sympathetic discharge and through suppressing se-
cretion of catecholamines from nerve endings in
a synapses. Through enlargement of afferent arte-
rioles and contraction of efferent arterioles, they in-
crease intraglomerular pressure and glomerular fil-
tration; relaxation of mesangial cells increases the
filtering surface. Moreover, natriuretic peptides in-
hibit the transport of sodium and water in proximal
tubules dependent on angiotensin II and, being
antagonists of vasopressin, they inhibit the trans-
port of water in collecting tubules and block reab-
sorption of sodium [11].
BNP as a screening test in the diagnosis
of left heart ventricle dysfunction
Testing the concentration of BNP in blood se-
rum enables the identification of the disease in its
early phase, which allows the commencement of
effective treatment and slows the changes in heart
construction [12]. An example of research that con-
firms that BNP assessment may be useful as a scre-
ening test in the general population is the study by
Nakamura et al. [13]. The authors confirmed that
BNP assessment is a useful test which efficiently
identifies patients with heart failure of origins con-
nected with heart function disorder documented by
clinical, electrocardiographic, radiological and echo-
cardiographic assessment, regardless of etiology
and degree of left ventricular dysfunction. In this
test, even a threshold value of BNP concentration
of 50 ng/L (14.4 pmol/L) managed to differentiate
unhealthy subjects from healthy ones (with an area
below AUC curve for ROC curve 0.97, sensitivity
87.7% and specifity 95.7%). Apart from echocardio-
graphy, determining the concentration of NT-proBNP
is of great importance, giving significant possibilities
for its use in differentiating diagnostics of dyspnoea.
In the research carried out by Januzzi et al. [14],
it was determined that a concentration of
NT-proBNP < 300 pg/mL virtually excludes struc-
tural heart disease which threatens life. In the re-
search by Miller et al. [15], levels of BNP in patients
with ischemic DCM and those in patients with DCM
of other than ischemic origin were compared. Con-
centrations of BNP were statistically significantly
higher in patients with ischemic cardiomyopathy
and amounted to 776 ± 91 pg/mL compared to 532 ±
± 85 pg/mL in patients with cardiomyopathy of non-
ischemic origin (p < 0.05). The death rate of car-
diovascular causes in 10 ± 1 months of observation
amounted to 48% in patients with heart failure of
ischemic origin and 23% in patients with primary
cardiomyopathy (p < 0.05). As can be seen, BNP
levels and death rates were significantly higher in
patients with cardiomyopathy of ischemic origin. In
research carried out by Ishikawa et al. [16], it was
determined that in patients with primary DCM the
survival rate studied within 42 months was signifi-
cantly higher in patients with high-sensitivity C-re-
active protein (hsCRP) level < l mg/L and BNP
level < 110 pg/mL. The relative risk of the occur-
rence of cardiac death in patients with hsCRP level
Table 3. Echocardiographic and Doppler
indicators of an unfavourable prognosis
in dilated cardiomyopathy [8]
Size and function of the left ventricle:
— left ventricular internal diameter in systole
> 55 mm and in diastole > 64 mm
— left ventricular end-diastolic volume > 5 mL/m2
— left ventricular end-systolic volume > 55 mL/m2
— left ventricular ejection fraction < 40%
— sphericity index < 1.5
— the maximal first derivative of left ventricular
pressure — dP/dt < 600 mm Hg/s
— TEI index (myocardial performance index) > 0.4
Diastolic function of the left ventricle:
— restrictive mitral inflow pattern
— pseudonormalization of mitral inflow
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> 1 mg/L and BNP level > 110 pg/mL amounted
to 15.8 (95% confidence interval 1.9–127.2) com-
pared to the group with BNP < 110 pg/mL and
hsCRP < 1 mg/L.
BNP is also assessed by heart ventricle filling
index. Pathophysiological premises suggest that
this non-invasive substitute marker is useful to
assess the pressure of filling the left ventricle. The
results of early research are not explicit. Part of the
research confirms the importance of the correlation
between BNP and hemodynamic parameters, as
well as of the decrease in BNP value proportional
to the decrease of pulmonary capillary wedge pres-
sure as a response to treatment [17, 18]. However,
results obtained by other researchers question the
usefulness of BNP assessment as a non-invasive
equivalent of pulmonary capillary wedge pressure
in the assessment of heart failure in various clini-
cal situations [19, 20]. At present, for the purposes
of clinical diagnosis, the following exclusive values
are proposed in patients over the age of 75: BNP <
< 70 pg/mL; NT-proBNP < 125 pg/mL. In addition, in
the case of acute dyspnoea, values of BNP < 100 pg/mL
or NT-proBNP < 300 pg/mL weigh against diagno-
sing a cardiological cause. According to Moe [21], in
patients over the age of 50, the proposed values con-
firming the diagnosis of heart failure, with high pro-
bability, amount to the following: BNP > 500 pg/mL
and NT-proBNP > 450 pg/mL; in patients in the age
range 50–75, the confirming values are the same both
for BNP and NT-proBNP and exceed 900 pg/mL.
Values useful in clinic diagnostics are compared in
Table 4.
Reports from June 2007 from the European
Congress of Heart Failure in Hamburg confirm the
role of NT-proBNP as a more useful marker of the
clinical course of heart failure than BNP. Further-
more, increased concentration of NT-proBNP se-
ems to be an unfavourable prognostic factor becau-
se intensifying pharmacological treatment in pa-
tients with increased concentration of NT-proBNP
did not improve the prognosis further. In the asses-
sment of heart failure, it is difficult to base decisions
only on values of natriuretic peptides because of the
variety of factors which can influence their concen-
tration in blood serum, such as demographic diffe-
rences in studied populations and the treatment
used, which at the given moment influences hemo-
dynamic conditions, including the pressure of he-
art ventricle filling. The treatment used influences
the concentration of natriuretic peptides to various
degrees; pharmaceutics used in heart failure decre-
ase their concentration by as much as 60% [22].
A significant element decreasing the credibility
(especially the diagnostic credibility) of natriuretic
peptides is the fact that many factors exist which
influence their concentration in blood serum. Fac-
tors independent of the degree of heart defect inc-
lude age (levels increase in direct proportion to
age), sex (levels are higher in women), glomerular
filtration (levels increase in kidney dysfunction) and
obesity (levels decrease in direct proportion to body
mass index; they reach lower values in obese pa-
tients and higher values in slimmer patients, not
only in cachectic patients) [23–26]. Ischemia as
a result of local hypoxia, changes in local pH, activa-
tion of local paracrine substances, occurrence of ar-
rhythmia, pulmonary artery thrombosis and other
factors resulting in right ventricle dysfunction incre-
ase the concentration of natriuretic peptides [27–29].
Lately, there have also been reports about
changes in the concentration of natriuretic pepti-
des in patients with stable heart failure; the diffe-
rences between consecutive tests of the same pa-
tient may even amount to 40–60% in the case of
tests for BNP and 33% in the case of those for
NT-proBNP [30].
The usefulness of assessing the concentration
of BNP or NT-proBNP during the choice of phar-
macotherapy intensity is the subject matter of the
following multicentre clinical research projects
which is being carried out at present: BATTLE-
-SCARRED (BNP-Assisted Treatment to Lessen
Serial Cardiac Readmissions and Death), RABBIT
Table 4. Diagnostic age-dependent values of brain natriuretic peptide (BNP) and N-terminal
prohormone brain natriuretic peptide (NT-proBNP) levels in patients with dyspnea.
Heart failure         Natriuretic   In general age Age ranges [pg/mL]
< 50 50–75
Diagnostic value BNP > 100 > 500 > 900
NT-proBNP > 300 > 450 > 900
Negative predictive value BNP < 70
NT-proBNP < 125
     peptide  < 75 [pg/mL]
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(Rapid Assessment utilizing Bedside BNP In Tre-
atment trial) and IMPROVE-CHF (Improved Ma-
nagement of Patients with Congestive Heart Failure
in Canada using NT-proBNP study). They are aimed
at assessing the concentration of BNP as an indica-
tor of treatment effects in heart failure.
The role of cardiac troponins in
diagnostics of dilated cardiomyopathy
At present, research is being carried out to
assess the role of cardiac troponin (cTn) concen-
tration in blood serum for diagnostics and risk as-
sessment in patients with DCM. The cardiac tro-
ponins are part of the troponin/tropomyosin com-
plex in thin filaments of heart muscle myofibrils.
This complex consists of troponin C (TnC), tropo-
nin I (TnI), troponin T (TnT) and tropomyosin. Tro-
ponins do not occur outside cells; therefore, their
occurrence in blood is a sensitive and peculiar indi-
cator of heart muscle cell defects.
During the necrosis of cardiomyocytes and pro-
teolytic degradation of contractile proteins, libera-
tion of the following substances occurs: free cTnT,
cTnT-cTnI-TnC (TIC) complex, fragments of cTnT,
cTnI-TnC (1C) complex and free cTnI. The total
concentration of cTnI amounts to 5–12 times more
than the concentration of free cTnI. The liberated
TIC complex quickly disintegrates to cTnT and IC
complex. Therefore, free cTnT, IC complex and
a certain amount of free cTnI occur in blood [31].
Table 5 presents the causes of increased concen-
trations of cTn in blood serum.
Nellessen et al. [32] assessed the usefulness
of tests for TnI as prognostic indicators in patients
with chronic heart failure. The mean concentration
of cTnI in blood serum of patients with congestive
heart failure amounted to 0.66 ± 1.8 ng/mL com-
pared to 0.11 ± 0.48 ng/mL in healthy volunteers
(p < 0.001). No significant differences were obse-
rved between patients with primary dilated cardio-
myopathy and those with cardiomyopathy of ische-
mic origin. It was also observed that liberation of
TnI was significantly higher in patients who died
afterwards (0.84 ng/mL vs. 0.56 ng/mL, p < 0.05).
The results confirm that the loss of cardiomyocy-
tes in progressing heart failure is connected with
the liberation of TnI, which can be an indicator of
an unfavourable prognosis. Miller et al. [33] deter-
mined that an increase of TnT concentration and
BNP concentration in patients with chronic heart
failure above the determined constant level is con-
nected with an increased risk of negative events,
such as death, heart transplant or hospitalization.
The group at highest risk include patients in which
an increase of TnT as well as BNP was observed.
The authors emphasized how important it is to
monitor those indicators during risk assessment in
patients with heart failure. Research carried out by
Sato et al. [34] confirmed that persistent increased
values of TnT in patients with dilated cardiomyopa-
thy indicate that degeneration of myocytes is in
progress, which is connected with the deterioration
of the patients’ clinical condition.
Pro-inflammatory cytokines in
dilated cardiomyopathy
During the last few years, more and more evi-
dence has emerged that cellular as well as humoral
autoimmune processes are involved in the patho-
genesis of DCM. Many patients display persistent
or chronic heart muscle inflammation described as
inflammatory cardiomyopathy according to World
Health Organization classification. The breaking
down of control mechanisms protecting against au-
toimmune reactions leads to the creation of antibo-
dies reacting directly with the tissue, and of T cells
which are harmful in the two following ways: indi-
rectly through cytotoxic cytokines, and directly as
cytotoxic cells [35]. An increased concentration of
inflammatory markers was observed not only in in-
flammatory cardiomyopathy but also in heart mu-
scle damage of another etiology. In the research
carried out by Mandi et al. [36], it was determined
that 85% of patients with DCM and ischemic car-
diomyopathy had increased levels of tumour necro-
sis factor alfa (TNF-a) and of interleukin-6 (IL-6)
in blood serum, while patients with hypertrophic
cardiomyopathy had increased levels of IL-6 only.
The mechanisms responsible for the development
Table 5. The causes of increase in serum troponin
concentration.
Myocardial infarction
Pulmonary embolism and right ventricle overload
Pericarditis
Myocarditis
Acute and serious chronic congestive heart failure
Septicemia and shock
Cardiotoxic drugs like adriamycin, doxorubicin,
5-fluorouracyl
Heart injury
Chronic renal failure
Hypothyroidism
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of DCM are still unknown. The high production of
pro-inflammatory cytokines in leukocytes of pa-
tients with DCM and the presence of TNF-a and
IL-6 in their heart tissue suggest the presence of
a strong immunology component in the pathogene-
sis of this disease. Interest in the role of pro-inflam-
matory cytokines in heart failure comes from the
observation that many symptoms of this disease
may be explained by the biological effects of these
molecules. If the expression of cytokines is high
enough, they can imitate certain properties of he-
art failure phenotype, including progressing left
ventricular function defect, pulmonary oedema, re-
structuring of the left ventricle, expression of fo-
etal genes and cardiomyopathy. Cytokine hypothe-
sis proves that their excessive expression partici-
pates in the progress of heart failure as
a consequence of left ventricular function defect. The
accumulation of cytokines, just like the accumulation
of neurohormones, may constitute a biological me-
chanism responsible for the progress of heart dise-
ase in patients with heart failure [6]. TNF-a also has
a potential cardiotoxic effect, mainly by influencing
the development of left ventricular dysfunction,
including pulmonary oedema and cardiomyopathy,
as a result of restructuring the left heart ventricle
(proved in experimental conditions), metabolic di-
sorders of heart muscle, uncoupling of receptor P
and adenyl cyclase, disorders of mitochondrion
energetic processes and activation of foetal genes
programme, as well as a decrease of blood flow in
lower limbs [37, 38]. Tentolouris et al. [39] asses-
sed a relationship between concentrations of IL-6,
TNF-a and functions of vascular endothelium in
patients with ischemic heart failure, DCM, and cor-
rect function of the left heart ventricle as well as in
a control group. The ability to dilate blood vessels
in response to congestion (RH% reactive hiper-
emia) or nitrates was recognized as an indicator of
blood vessel dilation ability dependent on, or inde-
pendent of, vascular endothelium. Blood flow in the
forearm was measured with plethysmography. Con-
centrations of IL-6 and TNF-a were statistically
higher in patients with ischemic cardiomyopathy
than in patients with cardiac ischemia without left
ventricular dysfunction (p < 0.05), and higher than
in subjects from the control group (p < 0.05). Con-
centration of IL-6 was significantly higher in pa-
tients with DCM compared to the control group
(p < 0.05). Concentration of TNF-a was statistically
higher in patients with DCM than in patients with
cardiac ischemia (p < 0.05) or in those from the
control group (p < 0.05). Reactive hyperemia
(RH%) was significantly lower in patients with
ischemic cardiomyopathy and DCM compared to
patients with coronary thrombosis without left ven-
tricular dysfunction (p < 0.05) and the control gro-
up (p < 0.001). The research proved that endothe-
lium dysfunction and inflammatory process expres-
sed with higher concentration of pro-inflammatory
cytokines occurred in ischemic heart failure as well
as in DCM. In patients with ischemic heart failure,
the observed endothelium dysfunction was greater
than in those with DCM, which may be a result of
atherosclerosis. In patients with DCM (33 of them
had coronary thrombosis as well), a significant re-
lationship between the levels of receptor for IL-2
(IL-2R) and left ventricular end-diastolic volume
was observed. After 24 months of observation,
a negative clinical course of the disease (death, ne-
cessary heart transplant, deterioration of clinical
condition) was observed in 17 of 76 assessed pa-
tients. In 75% of patients with a negative course of
the disease, concentrations of the receptor for IL-2
soluble in blood serum were increased (£ 800 pg/mL)
compared to 6% of patients with a stable clinical
course of the disease. Increased concentration of
sIL-2R in patients with DCM turned out to be an
independent factor of a negative clinical course of
the disease [40]. Brooksbank et al. [41] noticed that
hyperproduction of TNF-a in patients with ische-
mic cardiomyopathy remains the same despite the
hemodynamic improvement obtained as a result of
standard therapy with diuretics, angiotensin conver-
ting enzyme inhibitors and beta-adrenolytics. It was
observed that modification of cytokine levels leads
to the improvement of heart function as a pump and
to the control of clinical symptoms of overt heart
failure. For instance, in the research carried out by
Gürgün et al. [42], 12-weeks of therapy with fluva-
statin decreased levels of TNF-a and IL-6 in pa-
tients with DCM and ischemic cardiomyopathy,
which was accompanied by clinical and hemodyna-
mic improvement. Significant changes in levels of
C-reactive protein (CRP) and BNP were not obse-
rved. Further research assessing the prognostic
value of inflammatory markers in patients with car-
diomyopathy and the influence of their pharmaco-
logical modification on levels of these substances
and the clinical condition of patients is necessary.
Using statin in patients with DCM without corona-
ry thrombosis was an independent factor of reducing
the general death rate (HR = = 0.38; CI = 0.18 ±
± 0.82; p = 0.0134) as well as the death rate from
cardiovascular origins (HR = 0.42; CI = 0.18 ± 0.95;
p = 0.037) [43]. In the research carried out by Sam-
pietro et al. [44], the authors assessed whether or
not low levels of HDL cholesterol and inflammation
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are related to idiomatic DCM. Coronary microcir-
culation in idiopathic DCM is impaired, probably be-
cause of vascular endothelial dysfunction. High-
-density lipoproteins (HDL) potentially regulate
functions of endothelium by modulating inflamma-
tory reactions and immunological response. In pa-
tients with idiomatic DCM, lower levels of HDL,
apolipoprotein A-I and apolipoprotein A-II, as well as
higher levels of triglycerides, were observed. The
levels of all studied inflammatory markers (CRP,
soluble intercellular adhesion molecule, soluble en-
dothelial leukocyte adhesion molecules) were signi-
ficantly higher in patients with idiomatic DCM than
in the control group, and they were negatively cor-
related with HDL. These results also weigh in fa-
vour of the potential role of HDL in microvascular
dysfunction of vascular endothelium in patients with
idiomatic DCM.
In diagnostics of heart failure, which is also of
DCM origin, researchers try to use other new
biochemical markers like osteopontin, which is
a protein involved in the restructurizing of the
extracellular matrix. The increased levels of this
protein turned out to be an unfavourable progno-
stic factor in heart failure [45].
Osteopontin plays an important role in myocar-
dial remodelling, by promoting collagen synthesis
and accumulation in experimental animal models.
In Satoh at al. research [46] osteopontin and
collagenase I mRNA levels were highly expressed
in the DCM group with large left ventricular end-
systolic diameter (LVESD ≥ 54.5 mm) or low left
ventricular ejection fraction (LVEF < 29.5%), com-
pared to the control group (p < 0.01), which means
that osteopontin may play a pivotal role in the de-
velopment of collagenase-I-induced cardiac fibrosis
and dysfunction in DCM.
Increased serum levels of carbohydrate anti-
gen 125 (CA125), a tumour marker associated with
ovarian cancer, are associated with the severity of
congestive heart disease and are also independent
predictive markers for re-hospitalization [47].
In the research by Núńez et al. [48], serum le-
vels of CA125 > 35 U/mL (established cut-off po-
int value) obtained in patients admitted with a dia-
gnosis of acute heart failure were shown to be an
independent predictor of mortality up to the
6-month follow-up.
In the research carried out by Filipiak et al. [49],
it was found that the simultaneous determination
of NT-proBNP and tumour antigen CA-125 gives
the highest predictive accuracy of death risk in he-
art failure. Subsequent observations, confirming the
negative influence of increased uric acid concentration
on prognostics in patients with heart failure, point
to the necessity of carrying out randomized clinical
research on the influence of pharmaceuticals which
decrease its concentration (e.g. allopurinol) on the
clinical course of heart failure and eventual impro-
vement in prognostics [50].
Summary
More efficient, simple, cheap and quick me-
thods for diagnostics and risk assessment in pa-
tients with heart failure are being sought. Creating
a panel of useful laboratory tests performed in this
group of patients will enable the start of early phar-
macological therapy, the implementation (depen-
ding on the results) of mechanical circulation sup-
port or resynchronizing therapy, and the selection
of patients who should be qualified to heart trans-
plant first. Because of numerous limitations and the
influence of extracardial factors, the determination
of the levels of one biochemical marker cannot be
relied upon as a universal and infallible criterion of
recognition. Perhaps researchers will manage to
select a set of laboratory tests which will enable the
recognition of cardiomyopathy at an early stage and
which will be used to monitor treatment efficiency
and to prognosticate. Nowadays it is recommended
that BNP and troponin measurements be taken;
perhaps future research will confirm the usefulness
of other potential prognostic markers like osteopon-
tin, Ca-125 and cytokines.
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